Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06551142 2026-05-22

PanTumor-101

Phase 1 Recruiting

845 enrolled

Tumor-Agnostic

Neoplasms

NCT06567782 2026-05-22

AZUR-4

Phase 2 Recruiting

120 enrolled

Gastrointestinal

Colonic Neoplasms

NCT06796907 2026-05-22

BEHOLD-2

Phase 1/2 Recruiting

305 enrolled

Tumor-Agnostic

Neoplasms

NCT05819892 2026-05-20

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Phase 1 Recruiting

21 enrolled

Gynecologic

Endometrial Neoplasms

NCT04165772 2026-05-13

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Phase 2 Recruiting

212 enrolled

Gastrointestinal

Rectal Neoplasms

NCT04774419 2026-05-13

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

Phase 2 Recruiting

62 enrolled

Gynecologic

Endometrial Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06023862 2026-05-06

DOVE

Phase 2 Recruiting

198 enrolled

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT07408063 2026-04-29

BeeHive

Phase 2 Recruiting

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Phase 1/2 Recruiting

37 enrolled

Gynecologic

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

Clinical Trials

JADE

PanTumor-101

AZUR-4

BEHOLD-2

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

I-SPY

DOVE

BeeHive

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma